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Abstract
Objectives: Appropriate patient selection is important to achieving good outcomes and obviating
futile surgery in patients with huge (≥10 cm) hepatocellular carcinoma (HCC). The aim of this study
was to identify independent predictors of futile outcomes, defined as death within 3 months of surgery
or within 1 year from early recurrence following hepatectomy for huge HCC.
Methods: The outcomes of 149 patients with huge HCCs who underwent resection during 1995–2012
were analysed. Multivariate logistic regression analysis was performed to identify preoperative inde-
pendent predictors of futility.
Results: Independent predictors of 3-month mortality (18.1%) were: total bilirubin level >34 lmol/l
[P = 0.0443; odds ratio (OR) 16.470]; platelet count of <150 000 cells/ml (P = 0.0098; OR 5.039), and
the presence of portal vein tumour thrombosis (P = 0.0041; OR 5.138). The last of these was the sole
independent predictor of 1-year recurrence-related mortality (17.2%). Rates of recurrence-related mor-
tality at 3 months and 1 year were, respectively, 6.3% and 7.1% in patients with Barcelona Clinic Liver
Cancer (BCLC) stage A disease, 12.5% and 14% in patients with BCLC stage B disease, and 37.8%
(P = 0.0002) and 75% (P = 0.0002) in patients with BCLC stage C disease.
Conclusions: According to the present data, among patients submitted to hepatectomy for huge
HCC, those with a high bilirubin level, low platelet count and portal vein thrombosis are at higher risk
for futile surgery. The presence of portal vein tumour thrombosis should be regarded as a relative
contraindication to surgery.
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Introduction
According to tumour size, hepatocellular carcinoma (HCC) is
defined as very early stage (<2 cm),1 early stage (<3 cm),1 large
(>5 cm),2,3 or huge (≥10 cm).4 The last designation carries a
poor prognosis because it is commonly associated with macro-
scopic vascular invasion, satellite nodules, and distant intra- or
extrahepatic metastasis.5 Among the many currently employed
classifications,6 the Barcelona Clinic Liver Cancer (BCLC)
classification is the most reliable system for predicting out-
comes, at least in patients with HCC in Western countries.1
This system is endorsed by the European Association for the
Study of the Liver (EASL) and the American Association of the
Study of Liver Disease (AASLD). According to the BCLC clas-
sification, surgical resection for huge HCC is indicated only in
patients who are classified as having stage A disease (i.e. with a
single tumour of any size), provided that they show the
absence of vascular invasion and extrahepatic disease upon
imaging, have liver function of Child–Pugh class A status, do
not show portal hypertension and are in good general health.*Chetana Lim and Philippe Compagnon are co-first authors.
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Nevertheless, many centres still claim that resection provides
the greatest survival benefit for selected patients with so-called
intermediate and advanced (BCLC stages B and C) huge HCC
(Table 1).3,5,7–13 In practice, the decision to proceed with
resection for huge HCC is based on two considerations: firstly,
the operative risk associated with surgery, and secondly, the
chance for longterm survival beyond that which might be
achieved with standard non-surgical treatments [i.e. a median
survival of 41 months with transarterial chemoembolization
(TACE)14 in patients with a BCLC stage B tumour or
12 months with sorafenib for patients with a BCLC stage C
tumour].15,16 Accordingly, the present authors consider liver
resection for huge HCC to be futile when it is followed by
either death within 3 months of surgery or recurrence within
1 year of resection (early recurrence-related mortality). Most
reports note pre-, intra- and postoperative factors as predictors
of prognosis, although intra- and postoperative data are of
course not available to aid patients in deciding whether to
accept or decline this high-risk surgery when liver resection is
initially considered. This situation was the impetus for the
present study, which analyses only data available before surgery
to identify independent predictors of 3-month mortality and
early recurrence-related mortality.
Materials and methods
Study population
From 1995 to 2012, 820 patients with HCC underwent hepatic
resection in two Western hepatobiliary units that use the same
criteria for performing resection: 419 patients underwent surgi-
cal resection carried out by any of five senior surgeons at
Henri Mondor Hospital (Creteil, France), and 401 patients
underwent surgical resection performed by any of three senior
surgeons at Paul Brousse Hospital (Villejuif, France). All proce-
dures were performed by two senior surgeons working in pairs.
The study population included 149 consecutive patients
(18.2%) with huge HCC (i.e. tumour diameter of ≥10 cm) and
excellent performance status with neither lymph node nor dis-
tant metastases. Data for additional surgical patients with
Table 1 Reported series (≥100 cases) of patients submitted to liver resection for huge (≥10 cm) hepatocellular carcinoma (HCC)
Study, Cases, n Tumour
size, mma
Cirrhosis, % BCLC stages
A/B/C, %b
Mortality
rate, %
Morbidity
rate, %
5-year OS
rate, %
5-year
RFS
rate, %
Eastern series
Poon et al. (2002)11
Hong Kong
120 138  30 26.7% NA/NA/16.7% 5%d 35% 27.5% 9.5%
Yeh et al.(2003)13
Taiwan
211 139  34 29.9% NA/NA/55.8% 4.3%i 16.1% 16.7% 12.7%
Chen et al. (2006)8
China
634 141  26 86.3% NA/NA/21.9% 2.2%f NA 18.2% NA
Lee et al. (2007)9
South Korea
100 133  30 NA 42%/32%/26% 0.2%i NA 31% 20%
Pandey et al. (2007)10
Singapore
166 130 (100–240) 48.2% NA/NA/61.4% 3%d NA 28.6% NA
Ariizumi et al. (2012)7
Japan
177 130 (10–24) 19.8% 30.5%/30%/39.5% 5.6%i NA 42% NA
Yang et al. (2009) 3
China
258 132  41 66.1% NA/NA/47.7% 0.78%e 10.9%c 33% 6%
Western series
Pawlik et al. (2005)5
USA
300 NA NA 22.3%/61.4%/16.3% 5%f NA 26.9% NA
Schrager et al. (2012)12
USA
130 142  38 39.8% NA/NA/52.4% 6.9%d 21.5%c 18.8% 11.5%
Present series (2014)
France
149 126  31 15.4% 32.2%/37.6%/30.2% 5.4%f/
14.8%g/
18.1%h
43.6% 42% 24.8%
aMean  SD or median (range).
bAs none of the studies categorized patients with huge HCC according to the BCLC classification, the present authors have classified these
patients according to the data provided in the respective articles (i.e. stage A includes single huge tumours; stage B includes huge HCC associ-
ated with intrahepatic metastases; stage C includes any tumour with a portal vein tumour thrombus).
cMajor complications only.
Definitions of mortality: din-hospital or 30-day mortality; ein-hospital mortality; f30-day mortality; g60-day mortality; h90-day mortality; idata not
available.
BCLC, Barcelona Clinic Liver Cancer; OS, overall survival; NA, not available; RFS, recurrence-free survival; SD, standard deviation.
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contralateral metastases (17 patients), extrahepatic metastases
(seven patients), or tumour thrombi in the main hepatic veins
or in the vena cava (11 patients) were excluded from the
analysis. Data on demographics, comorbidities, liver diseases,
tumour characteristics, mortality, morbidity and survival out-
comes were retrieved from the prospective database of each
centre. This retrospective study was approved by the institu-
tional review boards of both centres and conformed to the
ethical guidelines of the 1975 Declaration of Helsinki.
Preoperative assessment
Total bilirubin, aspartate aminotransferase (AST), alanine ami-
notransferase (ALT) and a-fetoprotein (AFP) levels and platelet
count were reported. Preoperative values for albumin and
prothrombin time were not recorded. Kidney function was
classified as normal (creatinine within the normal range) or
abnormal. Patients were transfused before surgery as necessary
to achieve a haemoglobin level within the normal range. Need
for preoperative transfusion was not recorded in the source
databases.
The Charlson Comorbidity Index (CCI) was used to classify
patients according to their comorbid conditions, as previously
described.17 Additional points were assigned for age-adjusted
CCI, as follows: 1 point for patients aged 50–59 years; 2 points
for patients aged 60–69 years, and 3 points for patients aged
70–79 years. Chronological age per se was not a contraindica-
tion for surgery.
The diagnosis of HCC was based on imaging findings and/
or tumour biopsy, as recommended.1,18 In each patient, the
tumour was staged using contrast-enhanced thoracic, abdomi-
nal and pelvic computed tomography (CT) scans, magnetic
resonance imaging (MRI), Doppler ultrasound (US) of the
liver, and bone scintigraphy. Preoperative assessment included
the determination of the number of nodules, the presence of
satellite nodules, the maximum tumour size and the presence
of portal vein tumour thrombosis. The last condition was diag-
nosed when the vein was enlarged19 and displayed a wash-in
and wash-out pattern in MRI20,21 and/or CT22 and/or con-
trast-enhanced Doppler US.22–24 Whenever a tumour biopsy
was performed, non-tumour liver tissue was also obtained to
determine the status of the underlying parenchyma.
Patients were stratified according to the BCLC staging
system (Fig. 1). Briefly, stage A included only single tumours.
Stage B included tumours that were associated with intrahepat-
ic metastases. Stage C included any tumour with a portal vein
tumour thrombus observed upon imaging.
Study design
The aim of this study was to identify independent preoperative
predictors of futile surgery, which is defined as surgery fol-
lowed by death within 3 months from any cause or death
within 1 year of surgery as a result of early tumour recurrence.
Multivariable logistic regression analysis was therefore used to
identify predictors among 13 preoperative factors (see Statisti-
cal analysis) potentially contributing to 3-month mortality
and/or early recurrence-related mortality.
Selection criteria for liver resection
Patients were selected for surgery if they fulfilled these criteria:
(i) an absence of prohibitive comorbidities; (ii) Child–Pugh
class A liver function, and (iii) planning of complete macro-
scopic resection combined with a sufficient future remnant
liver volume upon preoperative CT scan volumetry. Portal vein
embolization (PVE) was performed when the expected
remnant liver represented <40% of the total non-tumour liver
volume.25 Preoperative TACE was never applied. Portal hyper-
tension was defined as oesophageal varices detected upon
endoscopy or splenomegaly, with a platelet count of <100 000
cells/ml.26 Portal hypertension was not considered an absolute
contraindication for hepatectomy and was discussed on a case-
by-case basis, provided that the patient had no history of
encephalopathy, ascites or variceal rupture. The present group’s
experience in this setting was recently reported.26
Liver resection
All resections were performed using a right subcostal open
approach.26 Major hepatectomy was defined as the resection
of three or more segments according to the Couinaud classifi-
cation.27
Three types of vascular control were employed in this series.
(i) In cases of hemiliver clamping, no clamping was applied to
the future remnant liver and thus clamping time was consid-
ered to be nil; similarly, clamping time was considered to be
nil when only the portal vein was clamped for portal deob-
struction, which maintained the blood flow within the hepatic
artery. (ii) The intermittent Pringle’s manoeuvre consisted of
alternating cycles of liver pedicle clamping (15 min in non-cir-
rhotic livers and 10 min in cirrhotic livers) and clamp release
(5 min), repeated until the end of the hepatectomy; the total
duration of clamping was recorded. (iii) Standard total vascu-
lar exclusion of the liver was performed for tumours in prox-
imity to the hepatocaval confluence.
Operative mortality, morbidity and follow-up
Postoperative mortality was defined as death within
3 months of surgery or at any time during hospitalization
for surgery. Complications were classified according to the
Dindo–Clavien system of classification.28 The durations of
stays in the intensive care unit (ICU) and in hospital were
recorded. Patients were defined as showing postoperative
liver failure if they fulfilled the 50–50 criteria on day 5 or at
any time thereafter.29 Massive ascites was defined as an
abdominal drain output of >500 ml/day for >3 days. Renal
insufficiency was defined as a serum creatinine level of
>150 lmol/l. Quality of life could not be assessed in this
retrospective study.
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Postoperative follow-up included quarterly clinical examina-
tions, liver function tests, measurement of AFP levels, Doppler
US, and either CT or MRI. No patient was lost from follow-
up. Site(s) and date of recurrence, if any, were recorded.
Pathological assessment
All specimens were reviewed by a single pathologist from each
centre (MS, JC), who were blinded to the postoperative and
longterm outcomes of the patients. Tumour characteristics
retrieved included: the number and size of lesions; the presence
of macroscopic and microscopic vascular invasion, and the
presence of satellite nodules.
Cost analysis
Costs were estimated based on reimbursements made to public
hospitals by the health care insurance system. The Groupe
Homogene de Malade [GHM; derived from the Diagnosis-
Related Group (DRG)] cost in euros was determined by the
hospitals and the Agence Technique de l’Information sur
l’Hospitalisation (ATIH). The GHM-based reimbursements
were calculated according to cost : charge ratios, using national
median charges and discharges for specific GHMs. For GHM
coding, a severity-refined GHM system was defined based on
the associated diagnosis, and major complications were consid-
ered as modifiers for various reimbursements. In the current
context, the GHM code 07C09 was used for hepatectomies for
malignant tumours. The cost of the stay for this specific group
was calculated according to the relevant diagnosis and associ-
ated complications.
The cost depends not only on the medical diagnosis, but
also on additional financial supplements calculated according
to the severity of the treated condition(s), as well as the
number of days spent in the ICU.
Statistical analysis
Continuous variables are presented as the mean  standard
deviation (SD) or as the median (range). Categorical variables
are presented as numbers and percentages. The chi-squared or
Kruskal–Wallis test was performed to compare clinical data, as
well as intra- and postoperative outcomes among patients
grouped according to BCLC classification. Survival curves were
computed using the Kaplan–Meier method and P-values for
(a) (b) (c)
Figure 1 Preoperative computed tomography scans showing (a) a huge Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular
carcinoma (HCC), (b) a BCLC stage B HCC (the white arrow indicates intrahepatic metastases), and (c) a BCLC stage C HCC (the white
star indicates tumour portal vein thrombosis)
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comparison were computed with the log-rank test. As the aim
of this study was to identify independent preoperative predic-
tors of death within 3 months from any cause or death within
1 year of surgery as a result of early tumour recurrence, Cox
multivariate analysis was not used in a survival analysis.
Multivariate logistic regression analysis was performed for
13 variables of potential prognostic importance to identify
independent predictors of 3-month mortality and early recur-
rence-related mortality. These variables included sex, age-
adjusted CCI, liver disease aetiology, status of the underlying
liver parenchyma, need for PVE, total bilirubin levels, platelet
counts, and the levels of AST, ALT and AFP, as well as tumour
size, number of nodules, and the presence of portal vein
tumour thrombosis. The selection of variables was based on a
univariate screen with a liberal P-value of ≤0.1; these variables
were then considered for multivariate analysis. A P-value of
<0.05 was considered to indicate statistical significance. Statisti-
cal analysis was performed using StatView Version 5.0 (SAS
Institute, Inc., Cary, NC, USA).
Results
Baseline characteristics of the patients
During the study period, 149 patients underwent liver resection
for huge HCC (Table 2). A total of 117 male (78.5%) and 32
female (21.5%) patients with a mean  SD age of 58  15
years (range: 16–89 years; median: 60 years) were included in
this study. Thirty-nine patients (26.2%) presented with positive
markers for hepatitis B viral infection, and nine patients (6%)
presented with positive markers for hepatitis C viral infection.
Alcohol consumption and metabolic syndrome were responsi-
ble for 6.7% and 4%, respectively, of liver disease in this
group. The median AFP level was 31.5 ng/ml (range:
1–1 140 000 ng/ml). The mean  SD age-adjusted CCI was
1.9  1.3, and 33 patients (22.2%) exhibited an age-adjusted
CCI of ≥3. Upon preoperative imaging, the mean  SD size of
the largest nodule and the mean  SD number of nodules
were 126.0  30.9 mm and 1.7  2.8 nodules, respectively.
Macroscopic portal vein tumour thrombosis was diagnosed in
45 patients (30.2%). Ten (6.7%) patients required preoperative
PVE in preparation for major hepatectomy.
Tumours were classified as BCLC stage A in 48 (32.2%)
patients, as BCLC stage B in 56 (37.6%) patients, and as BCLC
stage C in 45 (30.2%) patients.
Surgical procedures
Major resections accounted for 123 (82.6%) of the 149 resec-
tions (Table 3). The mean  SD number of resected segments
was 3.8  1.3 segments (median: 4.0 segments). Some form of
vascular clamping involving ischaemia in the remaining liver
was required in 117 (78.5%) patients, whereas 32 (21.5%)
patients did not require clamping. Intermittent hepatic pedicle
clamping was applied in 73 (49%) patients, and total vascular
exclusion of the liver was required in 44 (29.5%) patients. The
mean  SD total duration of ischaemia was 35.23  24.11
min. Sixty-six (44.3%) patients received a transfusion of a
mean  SD of 2.2  4.4 units of blood. The mean  SD
duration of surgery was 241  83.8 min.
Mortality and morbidity
Three-month mortality
Mortality at 1 month post-surgery was 5.4% (eight of 149
patients) (Tables 3–5). An assessment of mortality at 3 months
post-surgery found that 27 patients (18.1%) had died within a
mean  SD of 42.2  22.5 days after surgery (median:
44 days; range: 2–90 days). Mortality rates at 3 months were
6.3%, 12.5% and 37.8% in patients with tumours of BCLC
stages A, B and C, respectively (P = 0.0002).
Univariate analysis revealed six preoperative factors that were
related to 3-month mortality with P-values of <0.1: total biliru-
bin of >34 lmol/l (P = 0.0028); a platelet count of <150 000
cells/ml (P = 0.0037); AST (P = 0.0022); AFP (P = 0.0618);
tumour size (P = 0.0062), and portal vein tumour thrombus
(P < 0.0001) upon preoperative imaging (Table 4). Multivariate
analysis identified three independent predictors of 3-month
mortality: total bilirubin >34 lmol/l [P = 0.0443; odds ratio
(OR) 16.470, 95% confidence interval (CI) 1.073–252.753]; a
platelet count of <150 000 cells/ml (P = 0.0098; OR 5.039, 95%
CI 1.477–17.193), and portal vein tumour thrombosis
(P = 0.0041; OR 5.138, 95% CI 1.678–15.728).
Early recurrence-related mortality
Among the 122 patients (45, 49 and 28 patients with tumours
classified as representing BCLC stage A, B and C disease,
respectively) who survived at least 3 months after surgery, 79
(64.8%) patients experienced recurrence. Overall, 28 patients
exhibited early recurrence (i.e. within 1 year of surgery).
Recurrence was intrahepatic, extrahepatic and both intra- and
extrahepatic in 10, nine and nine patients, respectively. Death
from recurrence occurred in 21 of the 122 patients (rate of
early recurrence-related mortality: 17.2%), within a mean time
of 6.6  2.4 months (range: 3.0–11.5 months). Rates of early
recurrence-related mortality were 7.1% (n = 3), 14% (n = 6),
and 75% (n = 12) in patients with tumours of BCLC stage A,
B and C disease, respectively (P = 0.0002).
A univariate analysis identified three risk factors for early
recurrence-related mortality: serum AFP level (P = 0.025); the
presence of multiple tumours (P = 0.084), and portal vein
tumour thrombosis (P < 0.0001) (Table 5). According to the
multivariate analysis, portal vein tumour thrombosis remained
the sole independent risk factor for early recurrence-related
mortality (P = 0.0005; OR 6.5, 95% CI 2.3–18.6).
Morbidity
A total of 84 complications were recorded in 65 patients
(morbidity rate: 43.6%). According to the Dindo–Clavien sys-
tem of classification, these complications were minor (33
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Grade I or II complications) in 31 patients (20.8%), major (20
Grade III or IV complications) in 17 patients (11.4%), and
resulted in death (Grade V) in 17 (11.4%) patients (with a
total of 31 complications). Morbidity rates were similar for the
three BCLC stages (P = 0.391).
For the entire series, the mean  SD durations of stays in the
ICU and hospital were 7.0  8.5 days and 15.0  9.3 days,
respectively. The durations of stays in the ICU and in hospital
(13.8  14.1 days and 20.7  11.9 days, respectively) in the
group of patients who died within 3 months of surgery were sig-
nificantly longer (P < 0.0001 and P = 0.0012, respectively) than
those in patients who survived beyond this period (5.7 
6.0 days and 13.9  8.4 days, respectively). The durations of
ICU stay were similar among the three BCLC stages (P = 0.965).
Mean  SD hospital length of stay differed significantly
amongst patients with BCLC stage A (12.8  7.7 days), B (13.7
 8.2 days) and C (19.2  11.2 days) disease (P = 0.0004).
Longterm results
Survival rates in the whole cohort
After a median follow-up of 17.5 months, 57 patients (25, 24
and eight patients with tumours representing BCLC stage A, B
Table 2 Baseline characteristics of 149 patients submitted to liver resection for huge (≥10 cm) hepatocellular carcinoma
Total cohort
(n = 149)
BCLC class A
(n = 48, 32.2%)
BCLC class B
(n = 56, 37.6%)
BCLC class C
(n = 45, 30.2%)
P-valuea
Patient characteristics
Age, years, mean  SD 58  15 58  16 59  16.5 57  12 0.522
Male/female, n (%) 117 (78.5%)/32
(21.5%)
36 (75%)/12
(25%)
48 (85.7%)/8
(14.3%)
33 (73.3%)/12
(26.7%)
0.248
CCI
Weighted index, mean  SD 0.26  0.49 0.28  0.5 0.19  0.4 0.33  0.5 0.353
Age-adjusted index, mean  SD 1.90  1.3 1.83  1.1 1.77  1.1 1.33  0.2 0.136
Aetiology of liver disease, n (%)
HBV infection 39 (26.2%) 14 (29.2%) 10 (17.9%) 15 (33.3%) 0.302
HCV infection 9 (6%) 2 (4.2%) 3 (5.4%) 4 (8.9%)
Alcohol 10 (6.7%) 4 (8.3%) 3 (5.4%) 3 (6.7%)
Metabolic syndrome 6 (4%) 0 5 (8.9%) 1 (2.2%)
Haemochromatosis 1 (0.7%) 0 1 (1.8%) 0
No liver disease 84 (56.4%) 28 (58.3%) 34 (60.7%) 22 (48.9%)
Status of underlying liver, n (%)
Normal 48 (32.2%) 17 (35.4%) 20 (35.7%) 11 (24.4%)
Chronic hepatitis or fibrosis 78 (52.3%) 25 (52.1%) 26 (46.4%) 27 (60%)
Cirrhosis 23 (15.4%) 6 (12.5%) 10 (17.9%) 7 (15.6%)
Portal vein embolization 10 (6.7%) 3 (6.3%) 4 (7.1%) 3 (6.7%) 0.984
Tumour characteristics
Macroscopic vascular invasion
at diagnosis
45 (30.2%) 0 0 45 (100%) 0.0001
Tumour size at diagnosis,
mm, mean  SD
126  30.9 136  37.3 143  36.4 164  48.3 0.0082
Tumour number at
diagnosis, mean  SD
1.7  2.8 1 2.4  4.4 1.5  1.1 0.0002
a-fetoprotein, ng/ml,
median (range)
31.5 (1–1 140 000) 14.5 (1–608 100) 28 (1–150 000) 500 (1–1 140 000) 0.01
Preoperative blood tests
Total bilirubin, lmol/l, mean  SD 16.78  34.84 12.78  7.13 20.63  56.97 16.41  7.97 0.013
AST, IU/l, mean  SD 83.57  93.30 59.40  80.50 73.55  92.94 119.40  97.05 <0.0001
ALT, IU/l, mean  SD 53.70  62.40 47.73  78.15 47.33  36.19 66.91  66.56 0.007
Platelet count per ml, mean  SD 294 000  250.2 267 500  102.5 335 500  392.3 276 500  130.9 0.916
aChi-squared or Kruskal–Wallis test as appropriate.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; CCI, Charlson Comorbidity Index; HBV,
hepatitis B virus; HCV, hepatitis C virus; SD, standard deviation.
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and C disease, respectively) were living and 90 patients had
died. Rates of overall survival in the whole cohort at 1, 3 and
5 years were 73%, 50% and 42%, respectively (Fig. 2). Rates of
recurrence-free survival in the whole cohort at 1, 3 and 5 years
were 51.1%, 36.9% and 24.8%, respectively (Fig. 2). Rates of
overall survival at 1, 3 and 5 years were 80.8%, 63.4% and
54.9%, respectively, in patients with BCLC stage A HCC,
(median overall survival: 81.7 months), 71.1%, 54% and
30.9%, respectively, in patients with BCLC stage B HCC (med-
ian overall survival: 38.9 months), and 30.8%, 20.5% and
15.4%, respectively, in patients with BCLC stage C HCC (med-
ian overall survival: 4.8 months) (P < 0.0001) (Fig. S1, online).
Rates of recurrence-free survival at 1, 3 and 5 years were 66%,
50% and 34.6%, respectively, in patients with BCLC stage A
Table 3 Intra- and postoperative data for 149 patients submitted to liver resection for huge (≥10 cm) hepatocellular carcinoma
Total cohort
(n = 149)
BCLC class A
(n = 48, 32.2%)
BCLC class B
(n = 56, 37.6%)
BCLC class C
(n = 45, 30.2%)
P-valuea
Intraoperative data
Type of resection, n (%)
Right hepatectomy 42 (28.2%) 11 (22.9%) 16 (28.6%) 15 (33.3%) 0.154
Extended right hepatectomy 40 (26.8%) 14 (29.2%) 12 (21.4%) 14 (31.1%)
Left hepatectomy 18 (12.1%) 5 (10.4%) 6 (10.7%) 7 (15.6%)
Extended left hepatectomy 12 (8.1%) 1 (2.1%) 5 (8.9%) 6 (13.3%)
Central hepatectomy 4 (2.7%) 2 (4.2%) 1 (1.8%) 1 (2.2%)
Left lobectomy 12 (8.1%) 5 (10.4%) 7 (12.5%) 0
Segmentectomy 21 (14.1%) 10 (20.8%) 9 (16.1%) 2 (4.4%)
Number of segments resected, mean  SD 3.8  1.3 3.6  2.0 3.6  1.7 4.2  1.1 0.0749
Major hepatectomy (≥3 segments), n (%) 123 (82.6%) 33 (68.8%) 40 (71.4%) 43 (95.6%) 0.0027
Vascular control, n (%) 0.0302
Total vascular exclusion 44 (29.5%) 15 (31.3%) 10 (17.9%) 19 (42.2%) 0.0271
Hepatic pedicle clamping 73 (49%) 22 (45.8%) 29 (51.8%) 22 (48.9%) 0.8325
No clamping 32 (21.5%) 11 (22.9%) 17 (30.4%) 4 (8.9%) 0.0317
RBCs transfused, units, mean  SD 2.20  4.40 2.08  3.41 2.14  5.83 2.53  3.17 0.038
RBC transfusion, n (%) 66 (44.3%) 21 (43.8%) 17 (30.4%) 28 (62.2%) 0.0059
Total ischaemia time, min, mean  SD 35.23  24.11 37.98  25.34 28.45  20.09 40.14  25.77 0.066
Operation time, min, mean  SD 241.0  83.8 250.9  85.5 239.0  83.9 232.0  86.0 0.593
Postoperative data, n (%)
1-month mortality 8 (5.4%) 3 (6.3%) 3 (5.4%) 2 (4.4%) 0.9282
2-month mortality 22 (14.8%) 3 (6.3%) 6 (10.7%) 13 (28.9%) 0.0049
3-month mortality 27 (18.1%) 3 (6.3%) 7 (12.5%) 17 (37.8%) 0.0002
Morbidity 65 (43.6%) 21 (43.8%) 21 (37.5%) 23 (51.1%) 0.391
Severity of complications (Dindo–Clavien
classification), n (%)
Grade I/II 31 (20.8%) 14 (29.2%) 8 (14.3%) 9 (20%) 0.571
Grade III/IV 17 (11.4%) 5 (10.4%) 7 (12.5%) 5 (11.1%)
ICU stay, days, mean  SD 7.0  8.5 5.7  5.2 7.6  9.3 8.0  10.0 0.965
Hospital stay, days, mean  SD 15.0  9.3 12.8  7.7 13.7  8.2 19.2  11.2 0.0004
Surgical margins R1, n (%) 40 (26.8%) 16 (33.3%) 10 (17.9%) 14 (31.1%) 0.153
Satellite nodules, n (%) 80 (53.7%) 0 49 (87.5%) 31 (68.9%) <0.0001
Microscopic vascular invasion, n (%) 101 (67.8%) 19 (39.6%) 37 (66.1%) 45 (100%) <0.0001
Capsule tumour, n (%) 112 (75.2%) 37 (77.1%) 45 (80.4%) 30 (66.7%) 0.267
Capsule effraction if present, n (%) 81 (72.3%) 19 (39.6%) 35 (62.5%) 27 (60%) 0.0012
aChi-squared or Kruskal–Wallis test as appropriate.
BCLC, Barcelona Clinic Liver Cancer; ICU, intensive care unit; R1, positive margin resection; RBC, red blood cells; SD, standard deviation.
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HCC, 52%, 42% and 25.2% respectively, in those with BCLC
stage B HCC, and 32.5%, 11.6% and 11.6%, respectively, in
those with BCLC stage C HCC (P = 0.0016).
Overall survival in patients who survived beyond the first
year
A total of 84 patients (56.4% of the entire cohort, including
36, 36 and 12 patients classified as presenting HCCs of BCLC
stages A, B and C, respectively) survived more than 1 year after
surgery. The 1-, 3- and 5-year overall survival rates in this sub-
group of patients were 100%, 74.5% and 57%, respectively,
with median overall survival of 84 months. Rates of overall
survival at 1, 3 and 5 years were 100%, 78% and 67%,
respectively, in patients with BCLC stage A HCC, 100%, 73%
and 42%, respectively, in patients with BCLC stage B HCC,
and 30.8%, 66.5% and 50%, respectively, in patients with
BCLC stage C HCC (P = 0.52).
Cost analysis
The mean  SD cost of hospitalization for surgery was
€17 918  10 173. When stratified according to BCLC stage,
mean costs of hospitalization were similar across the three
groups (€17 121  8573, €17 783  11 332, and €18 938 
10 359 in patients with disease of BCLC stages A, B and C,
respectively (P = 0.451). Patients who died within 3 months of
surgery incurred significantly higher total charges
Table 4 Univariate and multivariate analysis of preoperative predictors of 3-month mortality in 149 patients submitted to liver resection
for huge (≥10 cm) hepatocellular carcinoma
3-month mortality Univariate
analysis
P-value
Multivariate analysis
Yes
n = 27 (18.1%)
No
n = 122 (81.9%)
P-value OR (95% CI)
Preoperative factors
Patient factors
Male gender, n (%) 22 (81.5%) 95 (77.9%) 0.6791
CCI weight-index ≥3, mean  SD 0.26  0.53 0.23  0.46 0.7674
CCI age-adjusted ≥3, mean  SD 1.519  1.252 1.615  1.153 0.6998
Portal vein embolization, n (%) 3 (11.1%) 7 (5.7%) 0.3126
Aetiology of liver disease, n (%)
HBV infection 10 (37%) 29 (23.8%) 0.7524
HCV infection 2 (7.4%) 7 (5.7%)
Alcohol 1 (3.7%) 9 (7.4%)
Metabolic syndrome 1 (3.7%) 5 (4.1%)
Haemochromatosis 0 1 (0.8%)
None 13 (48.1%) 71 (58.2%)
Preoperative blood tests
Total bilirubin >34 lmol/l, n (%) 3 (11.1%) 1 (0.8%) 0.0028 0.0443 16.470 (1.073–252.753)
Platelet count <150 000/ml, n (%) 8 (29.6%) 11 (9%) 0.0037 0.0098 5.039 (1.477–17.193)
AST, IU/l, mean  SD 134.6  128.0 72.3  80.2 0.0022 0.8030
ALT, IU/l, mean  SD 59.8  58.3 52.4  63.4 0.5911
a-fetoprotein, ng/ml, mean  SD 83 257  2 502 497 27 537  96 306 0.0618 0.4593
Tumour factors
Maximum tumour size, mean  SD 167.2  46.0 142.9  39.8 0.0062 0.2184
Single versus multiple tumours, n (%) 22 (81.5%)/5 (18.5%) 100 (82%)/22 (18%) 0.9527
Macroscopic vascular invasion, n (%) 17 (63%) 28 (23%) <0.0001 0.0041 5.138 (1.678–15.728)
Tumour number, mean  SD 1.5  1.6 1.7  3.0 0.6927
Status of underlying liver parenchyma, n (%)
Normal 7 (26%) 41 (33.6%) 0.2385
Chronic hepatitis or fibrosis 13 (4.1%) 65 (53.2%)
Cirrhotic liver 7 (26%) 16 (13.1%)
95% CI, 95% confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCI, Charlson Comorbidity Index; HBV, hepa-
titis B virus; HCV, hepatitis C virus; SD, standard deviation.
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(€121 806  499 579; median: €27 174; range: €10 551–
2 670 000) compared with the 122 patients who survived
beyond 3 months (€37 390  239 421; median: €12 501;
range: €9251€–2 670 000) (P < 0.0001).
Discussion
This is the first study to analyse outcome variables in the
setting of huge HCC and to use only those variables avail-
able before surgery. The present data show that good long-
term survival outcomes (57% at 5 years, with median
survival of 84 months) can be achieved with surgery in
patients with huge HCC if they survive the first year after
resection.
As clinicians await a consensus definition of futility, physio-
logic futility remains the most strictly defined type of futility30
and refers to treatment that should not be offered31 because it
cannot be expected to provide any survival benefit to the
patient. On this basis, the present group has defined the out-
come of surgery for huge HCC as futile if death occurs within
1 year of resection. This timeframe was subdivided into two
periods reflecting the ‘real-life’ situation, based on, respectively,
3-month mortality and early recurrence-related mortality
(within 1 year of resection) for survivors of the postoperative
Table 5 Univariate and multivariate analyses of preoperative predictors of early recurrence-related mortality in 149 patients submitted to
liver resection for huge (≥10 cm) hepatocellular carcinoma
Early mortality Univariate analysis
P-value
Multivariate analysis
Yes
n = 21
No
n = 101
P-value OR (95% CI)
Preoperative factors
Patient factors
Male gender, n (%) 16 (76.2%) 79 (78.2%) 0.839
CCI weight-index ≥3, mean  SD 0.31  0.70 0.24  0.43 0.599
CCI age-adjusted ≥3, mean  SD 1.94  1.40 1.96  1.25 0.944
Portal vein embolization 1 (4.8%) 6 (5.9%) 0.833
Aetiology of liver disease, n (%)
HBV infection 5 (23.8%) 24 (23.8%) 0.451
HCV infection 3 (14.3%) 4 (4%)
Alcohol 1 (4.8%) 8 (7.9%)
Metabolic syndrome 0 5 (5%)
Haemochromatosis 0 1 (1%)
Normal liver 12 (57.1%) 59 (58.4%)
Preoperative blood tests
Total bilirubin >34 lmol/l, n (%) 0 1 (1%) 0.647
Platelet count <150 000/ml, n (%) 2 (9.5%) 9 (8.9%) 0.929
AST, IU/l, mean  SD 88  72 69  82 0.33
ALT, IU/l, mean  SD 59  77 51  61 0.594
a-fetoprotein, ng/ml, mean  SD 70 027  154 598 18 338  76 446 0.025 0.192
Tumour factors
Maximum tumour size, mm, mean  SD 153.6  50.5 140.8  37.1 0.181
Multiple tumours, n (%) 7 (33.3%) 17 (16.8%) 0.084 0.159
Macroscopic vascular invasion, n (%) 12 (57.1%) 16 (15.8%) <0.0001 0.0005 6.5 (2.3–18.6)
Tumour number, mean  SD 1.9  1.5 1.7  3.2 0.828
Status of underlying liver parenchyma, n (%)
Normal 6 (28.6%) 35 (34.7%) 0.876
Chronic hepatitis or fibrosis 4 (19%) 54 (53.5%)
Cirrhotic liver 11 (52.4%) 12 (11.9%)
95% CI, 95% confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CCI, Charlson Comorbidity Index; HBV, hepa-
titis B virus; HCV, hepatitis C virus; OR, odds ratio; SD, standard deviation.
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period. The present analyses identified high levels of total
bilirubin, a low platelet count, and portal vein tumour throm-
bosis as independent predictors of 3-month operative mortal-
ity, whereas the last condition was the sole independent
predictor of early recurrence-related mortality.
Although independent predictors of operative mortality have
been previously reported (for a review, see32), the existing
series concentrate on pre-, peri- and postoperative prognostic
criteria. In practice, only preoperative data are available to aid
a given patient in making the decision on whether to accept or
decline surgery.33 Therefore, these preoperative data were anal-
ysed in the present work to achieve the present study’s objec-
tive (i.e. to identify predictors of futile surgery). The 3-month
mortality rate observed in the present series (18.1%) is consid-
erably higher than rates reported in other surgical series of
huge HCC, which range from 0% to 6.9% (Table 1). By
contrast with the majority of these series, the present study
analysed operative mortality at 3 months rather than at
1 month following surgery, as the latter time-point underestimates
the true risk of liver surgery by at least 50%.34–36 Similarly, the
operative mortality rate recorded in the present series was 3.3-
fold higher when measured at 3 months (18.1%) than at
1 month (5.4%). To refine the indications for surgery and to
compare the present data with those in most reported series of
patients with huge HCC (Table 1), the present analysis has
described patients in terms of not only their tumour size, but
also their BCLC classification. In patients in the present series
with BCLC stage A HCC (32% of patients), 3-month mortality
was 6.2% and early recurrence-related mortality was 7.1%
(three of 42 survivors); the actuarial survival rate was 54.9% at
5 years. These results, which are concordant with those of
other series, confirm that patients with BCLC stage A HCC are
optimal candidates for surgery, regardless of tumour size, even
when the tumour exceeds 10 cm in diameter.37 Until recently,
patients with BCLC stage B HCC were treated with TACE,
which achieves a significant increase in survival compared with
best supportive care (median survival: 20 months versus
16 months).38 Even more recently, in a randomized study, Yin
et al.14 showed that patients with BCLC stage B HCC treated
with surgical resection exhibited a median survival of
41 months, which is significantly longer than the median
survival of 14 months reported for those treated with TACE.
Multivariate analysis identified type of treatment as an inde-
pendent predictor of survival, with a 2.3-fold higher likelihood
of mortality observed for patients treated with TACE. The
present results for the subset of patients with BCLC stage B
HCC (operative mortality: 12.5%; early recurrence-related
mortality: 14%; 5-year survival: 42%, with a median overall
survival of 38.9 months) are concordant with those of Yin
et al.,14 and thus this group will continue to propose surgery
for this subset of patients with huge HCC.
Sorafenib is recommended by the current EASL and AASLD
guidelines as the primary standard of care for advanced HCC
(BCLC stage C). In this context, the median lengths of survival
achieved in two randomized trials15,16 comparing the outcomes
of sorafenib treatment with those of placebo care were
10.7 months versus 7.9 months (P < 0.001) (Llovet et al.15)
and 6.5 months versus 4.2 months (P = 0.014) (Cheng
et al.16). Despite the lack of robust evidence, the present
authors continue to offer surgery, as do others, to selected
patients with BCLC stage C tumours. In the present study,
3-month mortality, early recurrence-related mortality and
5-year survival rates were 37.8%, 75% and 15.4%, respectively,
in patients with BCLC stage C HCC. Although surgery can be
expected to show better results than treatment using sorafenib,
the results achieved in ‘non-ideal’ candidates for surgery are
far from the ‘ideal results’ targeted by the BCLC treatment
guidelines.39–41 Many modifications to the perioperative man-
agement of these patients might be implemented to improve
the current outcomes of surgery (see below). Considering the
identified predictors of 3-month mortality, the present group
is now reluctant to perform surgery in patients with huge
HCC who exhibit increased bilirubin levels (>34 lmol/l) and/
or a low platelet count (<150 000 cells/ml). For patients with
low platelet counts, the reported success of neoadjuvant splenic
artery embolization42 or even splenectomy43 to increase the
preoperative platelet count needs to be confirmed by further
studies. Additional studies are also needed to assess the use of
eltrombopag, which is efficient as a preparation for invasive
procedures in patients with cirrhosis and a low platelet
count.44 Although beyond the scope of the present study, it is
worth mentioning other measures which should be evaluated,
including: (i) an objective measure of the patient’s nutritional
status and pre- and postoperative optimization;45–48 (ii) thor-
ough evaluation of portal hypertension and liver functional
reserves before resection, including measurement of the hepatic
venous pressure gradient49 and tests to determine the indocya-
Figure 2 Overall and recurrence-free survival in 149 patients
submitted to resection for huge (≥10 cm) hepatocellular carcinoma
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nine clearance rate;50 (iii) more liberal application of PVE,
even when the future remnant liver volume seems sufficient, as
a test of the regenerative potential of the future remnant liver
and, more importantly, so that the regeneration of the future
remnant liver precedes hepatectomy by several weeks, and (iv)
the implementation of conditioning manoeuvres that are either
systemic or that target the remnant liver in order to condition
the liver against intraoperative ischaemia–reperfusion injury
subsequent to vascular clamping.51,52 In low-risk patients with
portal vein tumour thrombosis, which is a surrogate for intra-
or extrahepatic metastatic disease, this group will continue to
offer surgery as this remains the best palliative treatment
currently available.53
Oncological results require to be improved because surgery
alone achieves low rates of longterm disease-free survival (24.8%
at 5 years). A multimodal management strategy involving sur-
gery might be explored, possibly including neoadjuvant chemo-
therapy, such as with licartine, which has been successfully used
in the setting of liver transplantation for HCC,54 an intraopera-
tive anterior approach,2,55 and adjuvant TACE of the remaining
liver.56,57 For huge HCC, the present authors remain reluctant
to apply preoperative TACE, even using a supra-selective
approach, as the size of the tumour has been found to be predic-
tive of rupture and even mortality following this procedure.58–60
There is a cost associated with death from surgery because
most deaths do not occur during or immediately after the
procedure. The present data show that patients who died
within 3 months of surgery incurred significantly higher costs
compared with patients who survived beyond this period.
The shortcomings of the present study include its retrospec-
tive nature. Additionally, a treatment selection bias that
favours surgery over other treatments cannot be ruled out
because the patients in this series were referred to two separate
tertiary surgical units. However, this bias remains limited as all
potential treatments were available at both centres and all cases
were discussed and managed after multidisciplinary meetings
during the study period. Another limitation of the study
includes the large range in the OR for bilirubin in the multi-
variate analysis used to identify independent predictors of
3-month mortality. This might be explained by the sample’s
inclusion of 27 patients who died in the postoperative course
and the fact that only four patients in this series were found to
have a high bilirubin level according to a bilirubin cut-off of
34 lmol/l. However, the presence of hepatic vein tumour
thrombus was not considered at all in this study because hepa-
tic vein tumour thrombosis, like portal vein tumour thrombo-
sis, is common in patients with large HCC.61 The present
authors expect further reports on the impact of hepatic vein
tumour thrombus on longterm outcomes in surgically resected
patients with huge HCC. The present study did not assess
quality of life following hepatectomy. Such a measure might
highlight those patients in whom resection provided a survival
benefit but sacrificed quality of life. Further investigation
should examine this important issue. A recent prospective
study showed not only that any physical impairments present
after surgery for HCC had returned to baseline at 6 months,
but also that, postoperatively, psychological quality of life
improved relative to the preoperative state.62
Conclusions
In conclusion, this study shows that acceptable survival rates
may be achieved in patients with huge HCC. The use of pre-
dictors of futile outcomes that are available before the decision
to proceed with this type of high-risk surgery may be of value
to improve patient counselling and patient selection, and may
help to negotiate the gap between technical resectability and
the clinical operability of huge HCCs. Patients with huge
HCCs classified as BCLC stage A are good candidates for sur-
gery. For patients with huge HCCs classified as BCLC stage B,
liver resection should be discussed on a case-by-case basis in
patients who exhibit either a low platelet count or a high bili-
rubin level. Although hepatectomies performed for huge BCLC
stage C tumours can be performed with reasonable longterm
survival rates if patients survive beyond the first year (survival
rate of 50% at 5 years), high rates of postoperative mortality
indicate significant risk. Even if the presence of portal vein
tumour thrombosis per se should not be regarded as an abso-
lute contraindication to surgery, this study suggests it should
be considered as a major negative prognostic factor in patients
with huge HCCs.
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